These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 11835461

  • 21. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A, Sanchez-Ramos J.
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract] [Full Text] [Related]

  • 22. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
    Nutt JG, Carter JH.
    Neurology; 2000 Jan 11; 54(1):247-50. PubMed ID: 10636162
    [Abstract] [Full Text] [Related]

  • 23. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Jan 11; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 24. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G.
    Praxis (Bern 1994); 2005 Oct 19; 94(42):1633-8. PubMed ID: 16277084
    [Abstract] [Full Text] [Related]

  • 25. New dopaminergic therapies for PD motor complications.
    Larson D, Simuni T.
    Neuropharmacology; 2022 Feb 15; 204():108869. PubMed ID: 34742740
    [Abstract] [Full Text] [Related]

  • 26. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [Abstract] [Full Text] [Related]

  • 27. Apomorphine: North American clinical experience.
    Stacy M.
    Neurology; 2004 Mar 23; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
    [Abstract] [Full Text] [Related]

  • 28. Use of apomorphine in Parkinson's disease.
    Stocchi F.
    Neurol Sci; 2008 Dec 23; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [Abstract] [Full Text] [Related]

  • 29. Apomorphine and diphasic dyskinesia.
    Durif F, Deffond D, Dordain G, Tournilhac M.
    Clin Neuropharmacol; 1994 Feb 23; 17(1):99-102. PubMed ID: 8149366
    [Abstract] [Full Text] [Related]

  • 30. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z, Kovács N, Komoly S.
    Ideggyogy Sz; 2013 May 30; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract] [Full Text] [Related]

  • 31. Agonists versus levodopa in PD: the thrilla of whitha.
    Montgomery EB.
    Neurology; 2003 Nov 25; 61(10):1462; author reply 1462-3. PubMed ID: 14638991
    [No Abstract] [Full Text] [Related]

  • 32. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C.
    Mov Disord; 2005 Nov 25; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [Abstract] [Full Text] [Related]

  • 33. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M, Moreau C, Salleron J, Devos D, Kreisler A, Mutez E, Simonin C, Annic A, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2014 Mar 25; 170(3):205-15. PubMed ID: 24594365
    [Abstract] [Full Text] [Related]

  • 34. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD.
    Pharmacotherapy; 1999 Nov 25; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [Abstract] [Full Text] [Related]

  • 35. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C, Zangger I, Fischer G.
    Schweiz Rundsch Med Prax; 1992 Aug 25; 81(35):1011-5. PubMed ID: 1410978
    [Abstract] [Full Text] [Related]

  • 36. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L, Poewe W.
    Acta Neurol Scand Suppl; 1993 Aug 25; 146():46-9. PubMed ID: 8101415
    [Abstract] [Full Text] [Related]

  • 37. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 38. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine.
    de Saint Victor JF, Pollak P, Gervason CL, Perret J.
    Mov Disord; 1992 Nov 15; 7(3):283-4. PubMed ID: 1620148
    [No Abstract] [Full Text] [Related]

  • 39. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M, Reichmann H, Riederer P.
    Mov Disord; 2005 May 15; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract] [Full Text] [Related]

  • 40. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S, Howard J, Di Rocco A.
    Mov Disord; 2010 Mar 15; 25(4):508-10. PubMed ID: 20014061
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.